SGLT2 inhibitor empagliflozin is shown to be safe and effective for treating patients who have suffered a heart attack
The SGLT2 inhibitor empagliflozin confers kidney-protective benefits and can therefore be given safely and effectively to patients when they are hospitalized for acute myocardial infarction (MI), a Mount Sinai-led global ...
Sep 2, 2024
0
0